Primary hyperparathyroidism: 7,000 years of progress

Cleveland Clinic Journal of Medicine

Volumn 72, Issue 12, 2005, Pages 1084-1098

  Levine, Michael A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CINACALCET; ESTROGEN; PARATHYROID HORMONE; RALOXIFENE;

ALBUMIN BLOOD LEVEL; ARTICLE; BONE DISEASE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE COURSE; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FRACTURE; GASTROINTESTINAL DISEASE; GOVERNMENT; HUMAN; HYPERCALCIURIA; KIDNEY DISEASE; PARATHYROID ADENOMA; PATIENT MONITORING; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIMARY HYPERPARATHYROIDISM; RISK REDUCTION; STONE FORMATION; THYROID SURGERY; TREATMENT INDICATION; UNITED STATES; ADENOMA; BLOOD; PARATHYROID TUMOR; REVIEW;

ADENOMA; CALCIUM; HUMANS; HYPERPARATHYROIDISM, PRIMARY; PARATHYROID HORMONE; PARATHYROID NEOPLASMS;

EID: 33644858505     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.12.1084     Document Type: Article

References (39)

1. Zink AR, Panzer S. Fesq-Martin M, Burger-Heinrich E, Wahl J, Nerlich AG. Evidence for a 7000-year-old case of primary hyperparathyroidism [letter]. JAMA 2005; 293:40-42.
2. Heath H 3rd. Clinical spectrum of primary hyperparathyroidism: evolution with changes in medical practice and technology. J Bone Miner Res 1991; 6:S63-S70.
3. Mallette LE, Bilezikian JP, Heath DA, Aurbach GD. Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore) 1974; 53:127-146.
4. Silverberg SJ, Bilezikian JP. Asymptomatic primary hyperparathyroidism: a medical perspective. Surg Clin North Am 2004; 84:787-801.
5. Hsu SC, Levine MA. Primary hyperparathyroidism in children and adolescents: the Johns Hopkins Children's Center experience 1984-2001. J Bone Miner Res 2002; 17:N44-N50.
6. Harman CR, van Heerden JA, Farley DR, Grant CS, Thompson GB, Curlee K. Sporadic primary hyperparathyroidism in young patients: a separate disease entity? Arch Surg 1999; 134:651-655.
7. Loh KC, Duh QY, Shoback D, Gee L, Siperstein A, Clark OH. Clinical profile of primary hyperparathyroidism in adolescents and young adults. Clin Endocrinol (Oxf) 1998; 48:435-443.
8. Lawson ML, Miller SF, Ellis G, Filler RM, Kooh SW. Primary hyperparathyroidism in a paediatric hospital. QJM 1996; 89:921-932.
9. Kollars J, Zarroug AE, van Heerden J, et al. Primary hyperparathyroidism in pediatric patients. Pediatrics 2005; 115:974-980.
10. Chan AK, Duh QY, Katz MH, Siperstein AE, Clark OH. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. Ann Surg 1995; 222:402-412.
11. Mollerup CL, Lindewald H. Renal stones and primary hyperparathyroidism: natural history of renal stone disease after successful parathyroidectomy. World J Surg 1999, 23:173-175.
12. Frokjaer VG, Mollerup CL. Primary hyperparathyroidism: renal calcium excretion in patients with and without renal stone disease before and after parathyroidectomy. World J Surg 2002; 26:532-535.
13. Bonnick SL. Bone Densitometry in Clinical Practice: Application and Interpretation. Totowa, NJ: Humana Press; 1998:32-34.
14. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Belle Mead, NJ: Excerpta Medica, Inc; 1998.
15. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341:72-75.
16. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312:1254-1259.
17. Ma YL, Cain RL, Halladay DL, et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001; 142:4047-4054.
18. Eigelberger MS, Cheah WK, Ituarte PH, Streja L, Duh QY, Clark OH. The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism: are they too limited? Ann Surg 2004; 239:528-535.
19. Goyal A, Chumber S, Tandon N, Lal R, Srivastava A, Gupta S. Neuropsychiatric manifestations in patients of primary hyperparathyroidism and outcome following surgery. Indian J Med Sci 2001; 55:677-686.
20. Chiang GY, Andrewes DG, Anderson D, Devere M, Schweitzer I, Zajac JD. A controlled, prospective study of neuropsychological outcomes post parathyroidectomy in primary hyperparathyroid patients. Clin Endocrinol 2005; 62:99-104.
21. Gerlach OC, Sondergaard SB, Vestergaard H, Jakobsen H, Nielsen SL. Myocardial perfusion defects and the left ventricular ejection fraction disclosed by scintigraphy in patients with primary hyperparathyroidism. World J Surg 2005; Epub Jun 16.
22. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:3326-3330.
23. Nilsson IL, Wadsten C, Brandt L, Rastad J, Ekbom A. Mortality in sporadic primary hyperparathyroidism: nationwide cohort study of multiple parathyroid gland disease. Surgery 2004, 136:981-987.
24. Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease - a review. Eur Heart J 2004; 25:1776-1787.
25. Silverberg SJ, Gao P, Brown I, LoGerfo P, Cantor TL, Bilezikian JP. Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88:4725-4730.
26. Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005; 132:359-372.
27. Debelenko LV, Zhuang Z, Emmert-Buck MR, et al. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 1997; 57:2238-2243.
28. Bilezildan JP, Potts JT Jr, Fuleihan G el-H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002; 87:5353-5361.
29. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery (erratum in N Engl J Med 2000; 342:144). N Engl J Med 1999; 341:1249-1255.
30. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 2000, 321:598-602.
31. Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004, 89:5415-5422.
32. Solomon BL, Schaaf M, Smallridge RC. Psychologic symptoms before and after parathyroid surgery. Am J Med 1994; 96:101-106.
33. Burney RE, Jones KR, Christy B, Thompson NW. Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels. Surgery 1999; 125:608-614.
34. Denham DW, Norman J. Cost-effectiveness of preoperative sestamibi scan for primary hyperparathyroidism is dependent solely upon the surgeon's choice of operative procedure. J Am Coll Surg 1998; 186:293-305.
35. Hallfeldt K, Trupka A, Gallwas J, Horn K. Intraoperative monitoring of intact parathyroid hormone during surgery for primary hyperparathyroidism [in German]. Zentralbl Chir 2002; 127:448-452.
36. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001; 16:113-119.
37. Chow CC, Chan WB, Li JK, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88:581-587.
38. Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:3319-3325.
39. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:135-141. Epub 2004 Nov 2.